CM
LUMO

Crestline Management’s Lumos Pharma, Inc. Common Stock LUMO Stock Holding History

Crestline Management’s Portfolio LUMO Stock Details LUMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-1,215
Closed -$263K – 172
2017
Q1 		$263K Buy
+1,215
New +$174K 0.05% 104

Other funds holding LUMO

First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CCI
Columbus Circle Investors $2.28B AUM 135.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BIM
Bogle Investment Management Newton Lower Falls, Massachusetts $63M AUM 51.97% 1-Year Est. Return

Crestline Management's LUMO Position: Q2 2017 in Review

Crestline Management sold out of Lumos Pharma, Inc. Common Stock (LUMO) in Q2 2017, closing a stake of 1,215 shares — an estimated $263K sold.

Crestline Management first reported a position in LUMO in Q1 2017 and held it in 1 quarter. The position peaked at $263K in Q1 2017. 110 funds tracked by Wall St. Rank hold LUMO as of Q2 2017.

  • Crestline Management reported no remaining Lumos Pharma, Inc. Common Stock position as of Q2 2017 after selling out during the quarter.
  • Crestline Management sold 1,215 Lumos Pharma, Inc. Common Stock shares in Q2 2017, an estimated $263K.
  • Crestline Management first reported a position in Lumos Pharma, Inc. Common Stock in Q1 2017 and held it in 1 quarter.
  • Crestline Management's Lumos Pharma, Inc. Common Stock position peaked at $263K in Q1 2017.
  • 110 funds tracked by Wall St. Rank held Lumos Pharma, Inc. Common Stock as of Q2 2017.

Based on Crestline Management's 13F filing for Q2 2017, filed 14 Aug 2017.